Imunon, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $500,000 | $500,000 |
| Research and development | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M |
| Operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M |
| Interest expense | — | — | $197,080 | $5.0M | $569,881 |
| Pretax income | $14.5M | $18.6M | -$20.8M | -$37.5M | -$22.2M |
| Income tax expense | — | — | -$1.3M | -$1.6M | -$1.4M |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M |
| Balance Sheet | |||||
| Cash and equivalents | $8.8M | $5.9M | $5.8M | $11.5M | $19.6M |
| Current assets | $10.7M | $8.0M | $18.2M | $36.8M | $51.9M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M |
| Current liabilities | $4.6M | $4.8M | $7.4M | $10.0M | $6.8M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M |
| Total debt | — | — | — | $6.0M | — |
| Stockholders' equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M |
| Depreciation and amortization | $291,908 | $240,175 | $248,154 | $731,629 | $702,918 |
| Stock-based compensation | $127,374 | $477,256 | $759,013 | $2.7M | $3.8M |
| Capital expenditure | $280,572 | $29,541 | $451,759 | $267,800 | $311,613 |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M |
| Impairments | — | — | — | $13.4M | — |
Shares outstanding 4.2M · Free float 31.9%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.